# Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

> **NCT00765323** · PHASE3 · TERMINATED · sponsor: **Endo Pharmaceuticals** · enrollment: 169 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Octreotide Implant
- **DRUG:** Sandostatin LAR Depot

## Key facts

- **NCT ID:** NCT00765323
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2011-02
- **Final completion:** 2011-06
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2013-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765323, "Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00765323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*